阿德福韦酯对HBV阳性肝细胞癌根治术后预后的影响

The effect of adefovir dipivoxil on the prognosis of HBV positive hepatocellular carcinoma

目的探讨阿德福韦酯对HBV阳性肝细胞癌根治术后预后的影响。方法回顾性分析2008年1月～2009年1月于我院行肝癌根治术的92例HBV阳性原发性肝癌患者,其中54例行阿德福韦酯治疗(观察组),38例未行任何抗病毒治疗(对照组)。所有患者随访,比较两组患者术后3年肝功能、肿瘤复发率及生存率差异。结果两组患者均无住院期间死亡。观察组1、2、3年的HBeAg血清学转换率及肝功能均较对照组明显改善;两组3年肿瘤复发率差异无统计学意义,但观察组的3年生存率及中位生存期(72.2%,30.6个月)显著高于对照组(50.0%,25.0个月)(P<0.05)。结论阿德福韦酯抗病毒治疗可明显改善HBV阳性肝细胞癌根治术后的肝功能及生存预后,值得临床推广应用。

Objective To evaluate the effect of adefovir dipivoxil on the prognosis of HBV positive hepatocellular carcino- ma （HCC）. Methods Ninty-two HBV positive HCC patients who had hepatectomy in our department from Jan 2008 to Jan 2009 were enrolled and grouped into treatment group（54 cases） versus control group （38 eases） in this retrospective study. All patients were followed up and the liver function, recurrence rates and survival rates in 3 years were compared. Results No death occurred during the hospitalization period in this study. The the HBeAg seroeonversion rates and liver function of treatment group were all significantly improved than control group. There is no difference in the recurrence rates but the survival rates and median survival time of treatment group （72.2%, 30.6 months） were significantly higher than those of control group （50.0%, 25.0 months）. Conclusion Anti-virus treatment with adefovir dipivoxil could significantly improve the liver function and 3-yrs survival rates of HBV positive HCC patients who had hepateetomy.